SCIASCIA THOMAS 4
4 · Trevi Therapeutics, Inc. · Filed Mar 12, 2025
Insider Transaction Report
Form 4
SCIASCIA THOMAS
Chief Scientific Officer
Transactions
- Award
Performance Stock Option (right to buy)
2025-03-10+32,000→ 32,000 totalExercise: $2.38From: 2025-03-10Exp: 2034-02-14→ Common Stock (32,000 underlying)
Footnotes (1)
- [F1]Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 100,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 32,000 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied.